Acacia Pharma Group plc Acacia Pharma Becomes New Industry Supporter Of The American Society Of Anesthesiologists
April 21 2021 - 12:00AM
UK Regulatory
TIDMACPH
Acacia Pharma Becomes New Industry Supporter of the American Society of
Anesthesiologists
Cambridge, UK and Indianapolis, US -- 21 April 2021, 07:00 CEST: Acacia
Pharma Group plc ("Acacia Pharma", the "Group" or the "Company")
(EURONEXT: ACPH), a hospital pharmaceutical company focused on the
development and commercialization of new products aimed at improving the
care of patients undergoing significant treatments such as surgery,
other invasive procedures or cancer chemotherapy, is proud to be named a
new Industry Supporter of the American Society of Anesthesiologists
("ASA" or the "Society").
Launched in 2010, ASA's Industry Supporter Program is limited to ten
organizations. Participation is intended for companies who want to stand
apart by showcasing high-level commitment to the education of physician
anesthesiologists, the anesthesia care team and advancement of the
specialty.
As an Industry Supporter, Acacia Pharma will help to establish a strong,
mutually beneficial relationship with the anesthesiology community,
strengthen collaboration between physician anesthesiologists and
industry, and add to the value the Society provides to patients and the
public, while providing invaluable year-round support of ASA programs
and priorities related to improving perioperative care.
Through the program, Acacia Pharma will have unique opportunities to
inform strategic dialogue with leaders in anesthesiology from around the
world and during major ASA events including the ANESTHESIOLOGY(R) annual
meeting and Practice Management(TM) conference.
Acacia Pharma has two FDA-approved anesthesiology products currently
being launched in the U.S. The first is a new dopaminergic antiemetic
approved for treatment and prophylaxis of postoperative nausea and
vomiting (PONV), targeted at addressing the major unmet need in the
rescue treatment of patients suffering with PONV. The second is a novel,
rapid on/rapid off and reversible benzodiazepine approved for procedural
sedation in adults undergoing procedures lasting up to 30 minutes, such
as colonoscopy and bronchoscopy.
"We are excited to welcome Acacia Pharma as a new ASA Industry Supporter,
" said ASA President Beverly K. Philip, M.D., FACA, FASA. "By working
with our Industry Supporters, we aim to improve perioperative care.
Acacia Pharma and our members working together will strengthen the
Society's priorities of advancing the specialty through patient safety
and practice initiatives."
"We are delighted to become an ASA Industry Supporter, the world's
pre-eminent organization representing anesthesiologists," commented
Acacia Pharma Chief Medical Officer Gabriel Fox, M.D. "This gives us a
greatly valued opportunity to work with anesthesiologists across the
country to improve the safety, outcomes and well-being of their
patients. We look forward to a successful partnership for years to come
and thank ASA for this opportunity."
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Mark Swallow, Frazer Hall, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 Citigate Dewe Rogerson
IR@acaciapharma.com +44 20 7638 9571
acaciapharma@citigatedewerogerson.com
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the
development and commercialization of new products aimed at improving the
care of patients undergoing significant treatments such as surgery,
other invasive procedures, or cancer chemotherapy. The Company has
identified important and commercially attractive unmet needs in these
areas that its product portfolio aims to address.
Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is
available in the US for the management of postoperative nausea &
vomiting (PONV).
BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV
benzodiazepine sedative is approved and launched in the US for use
during invasive medical procedures in adults lasting 30 minutes or less,
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion
UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV) has
successfully completed one proof-of-concept and one Phase 2 dose-ranging
study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D
operations are centred in Cambridge, UK. The Company is listed on the
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker
symbol ACPH.
Acacia Pharma Group plc
The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United
Kingdom
Company number 9759376
www.acaciapharma.com
About The American Society Of Anesthesiologists
Founded in 1905, the American Society of Anesthesiologists (ASA) is an
educational, research and scientific society with more than 54,000
members organized to raise and maintain the standards of the medical
practice of anesthesiology. ASA is committed to ensuring physician
anesthesiologists evaluate and supervise the medical care of patients
before, during and after surgery to provide the highest quality and
safest care every patient deserves.
For more information on the field of anesthesiology, visit the American
Society of Anesthesiologists online at asahq.org
https://www.globenewswire.com/Tracker?data=XZk39bwcaFucGP-0FT0l3muBl4O0QH1G_zAp3ZifMKguKzAZmnB9KI10whHGQINOOzDH8pDueJjVcKGUGy2VcQ==
. To learn more about the role physician anesthesiologists play in
ensuring patient safety, visit asahq.org/
https://www.globenewswire.com/Tracker?data=XZk39bwcaFucGP-0FT0l3meZN6jk_9gSu2t7oFwOEucshbRcGh21h3NHJRvqdnHpgbmKnEwnoIVwgeHwuZpaWVYrGeCk0kpxVTnNhe-gYIM=
MadeforThisMoment
https://www.globenewswire.com/Tracker?data=40PSLDc8Ac2UOEjOJ9mxGmL_W9hu-R8nyAIFs2W2kz_PaPQ0zGFN80OPNIGwsTRObnL5JeSGoltF8Bvzamc5hD5PHd0HlaSF0PCTfchvKxIZrPKfqIec78vu8DLjAcaI
. Like ASA on Facebook
https://www.globenewswire.com/Tracker?data=CgwHa2Uiv2oySf-EX9c4n99kLF9IMEpNUbneTkzxC4zLG0m3t5uTwmdM0sHqskNy5PjfDnAFeCl0CBEPqDsTSnyqcxIiJCcIgzHJxVrhf4YQ0agJ3WVVB5m8asvynB8V
, follow ASALifeline
https://www.globenewswire.com/Tracker?data=PGTD9fBNiTjFDtFYtWD3X1dKWdjRJ1EDE61wxIATeucxkIcXxyHDbZIGeebkIT5rC1wHx1mz_-Ye0LdRdp-BXRYetF7Mo--ROtqX0irKd4k=
on Twitter. ASA hosts the ANESTHESIOLOGY(R) annual meeting
https://www.globenewswire.com/Tracker?data=K81xlx8jsGgqfHt12_WcefA0AppXWcSR1g3endaAAWMUHjPi0b8Os0NlAwPXbAVFLQ6lwS4AVwcEJhLex92Vmpg79Lwwy4YACqLVYVn12oikqLzUeAFPiHMceYEYxFdRN8mdyWfl9cGy3iMhGN2Krw==
, the largest, most comprehensive conference in the specialty with
world-class education, the latest research and innovations, and the
chance to recharge with colleagues, Oct. 8-12, 2021 in San Diego. Unable
to attend in person, sign up for the Virtual Track which will offer a
curated selection of presentations.
Attachment
-- NL - ACPH Press release ASA 210421
https://ml-eu.globenewswire.com/Resource/Download/4405770e-f3c1-4928-af1b-e5d8df1af6ff
(END) Dow Jones Newswires
April 21, 2021 01:00 ET (05:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024